Robotic vs Laparoscopic D3-D4 Lymphadenectomy for Colorectal Cancer
Robotic Versus Laparoscopic D3-D4 Lymphadenectomy for Patients With Advanced Colorectal Cancer… A Randomized Prospective Clinical Trial for the Comparison of Oncologic and Functional Outcomes
1 other identifier
interventional
286
1 country
1
Brief Summary
Approximately one third of patients with colorectal cancer are diagnosed as locally advanced stage with metastasis to N3 - N4 lymph nodes requiring a D3 - D4 lymphadenectomy. Our previous study has indicated that, by laparoscopic approach, the extended abdomino-iliac lymphadenectomy, the so-called D3-D4 lymph node dissection, could be performed with quick convalescence and similar oncologic efficacy for the treatment of advanced recto-sigmoid cancer with metastatic lesions over N3-N4 lymph nodes, as compared with traditional open surgery. In the present study, the investigators will further compare the oncologic and functional outcomes of robotic versus laparoscopic approach in performing such challenging surgical procedures for patients with advanced colorectal cancer requiring a D3-D4 lymphadenectomy through a randomized prospective clinical trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable colorectal-cancer
Started Jun 2020
Typical duration for not_applicable colorectal-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 19, 2020
CompletedFirst Submitted
Initial submission to the registry
July 9, 2023
CompletedFirst Posted
Study publicly available on registry
July 27, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2024
CompletedAugust 1, 2023
April 1, 2023
3.9 years
July 9, 2023
July 27, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The time to recurrence of cancer after curative resection
The duration between the time of curative resection and the time to cancer recurrence
Up to 3 years
Secondary Outcomes (5)
the number of dissected lymph nodes
An average of 7 days
The distribution of dissected lymph nodes
An average of 7 days
Functional recovery
Up to 6 months
The overall costs of both minimally invasive surgical approaches
Through patients' discharge from hospital, an average of 7 days
Assessment of disability
12 months
Study Arms (2)
Laparoscopic surgery
NO INTERVENTIONThe patients will undergoing laparoscopic surgery for the treatment of locally advanced colorectal cancer
Robotic group
ACTIVE COMPARATORThe patients will undergoing robotic surgery for the treatment of locally advanced colorectal cancer
Interventions
The patient group undergoing robotic surgery for the treatment of locally advanced colorectal cancer
Eligibility Criteria
You may qualify if:
- Histopathologically proved adenocarcinoma located at upper rectum (above pelvic peritoneal reflection), recto-sigmoid junction, or distal sigmoid colon (generally 10 to 25 cm above anal verge). Only recto-sigmoid cancers above the peritoneal reflection were investigated because the lymphatic drainage of upper rectum and distal sigmoid colon was along the inferior mesenteric artery to the para-aortic area, and therefore the extent of surgical resection and lymph node mapping were standardized.
- Clinically TNM stage III cancers.
- Curative robotic or laparoscopic surgery.
- American Society of Anesthesiology (ASA) class I to III patients.
- Age between 50 and 75 years. This was because patients \>50 years old are generally deemed to be over the reproductive age, and the D3 dissection was considered too aggressive for patients older than 75 years.
- Patients who are willing to receive minimally invasive surgical procedures to treat their rectosigmoid cancer.
You may not qualify if:
- Tumors located at other anatomic positions;
- Emergency or palliative surgery;
- Evidence of disseminated disease or adjacent organ invasion;
- Primary tumor mass ≥8 cm in diameter;
- Morbidly obese patients (body mass index ≥40 kg/m2);
- Previous major surgery of lower abdomen.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Jin-Tung LIANG
Taipei, 886, Taiwan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jin-Tung LIANG, PhD
National Taiwan University Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- No masking
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Division of colorectal surgery, department of surgery, National Taiwan University Hospital
Study Record Dates
First Submitted
July 9, 2023
First Posted
July 27, 2023
Study Start
June 19, 2020
Primary Completion
May 1, 2024
Study Completion
May 1, 2024
Last Updated
August 1, 2023
Record last verified: 2023-04